In Long-Awaited Guidance, FDA Lays Out Approval Path For Drugs And Companion Dxs
This article was originally published in The Pink Sheet Daily
Executive Summary
Draft document addresses how FDA expects drugs and devices to be developed contemporaneously and how those products will be reviewed simultaneously by the relevant regulatory centers at FDA with collaboration across divisions.
You may also be interested in...
A “Breakthrough” Reality Check: Sponsors Seek FDA Flexibility On Manufacturing, Diagnostics
FDA’s much-anticipated guidance on expedited programs for drug development fills in some blanks on the new breakthrough designation, but simply advising sponsors they will need to pick up the pace on manufacturing plans and development of companion diagnostics leaves aspiring applicants wanting more, stakeholders said at DIA.
FDA Reorganization Creates Prominent Roles For Mercy Hospital's Spielberg, CDER's Autor
Commissioner Hamburg places drug, biologics, devices and tobacco centers under Steven Spielberg's directorate; Deborah Autor becomes deputy commissioner for global regulatory operations and policy.
FDA Reorganization Creates Prominent Roles For Mercy Hospital's Spielberg, CDER's Autor
Commissioner Hamburg places drug, biologics, devices and tobacco centers under Steven Spielberg's directorate; Deborah Autor becomes deputy commissioner for global regulatory operations and policy.